Barclays’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-111,461
| Closed | -$19.2M | – | 4954 |
|
|
2021
Q3 | $19.2M | Buy |
111,461
+72,937
| +189% | +$9.54M | 0.01% | 906 |
|
|
2021
Q2 | $4.83M | Buy |
38,524
+8,161
| +27% | +$1.03M | ﹤0.01% | 1604 |
|
|
2021
Q1 | $4.12M | Buy |
30,363
+22,846
| +304% | +$2.95M | ﹤0.01% | 1686 |
|
|
2020
Q4 | $961K | Buy |
7,517
+4,648
| +162% | +$545K | ﹤0.01% | 2784 |
|
|
2020
Q3 | $322K | Sell |
2,869
-10,271
| -78% | -$1.02M | ﹤0.01% | 3537 |
|
|
2020
Q2 | $1.25M | Sell |
13,140
-32,285
| -71% | -$3.11M | ﹤0.01% | 2550 |
|
|
2020
Q1 | $4.08M | Sell |
45,425
-25,651
| -36% | -$1.99M | ﹤0.01% | 1646 |
|
|
2019
Q4 | $3.77M | Sell |
71,076
-21,470
| -23% | -$979K | ﹤0.01% | 2318 |
|
|
2019
Q3 | $3.66M | Buy |
92,546
+49,720
| +116% | +$2.16M | ﹤0.01% | 2154 |
|
|
2019
Q2 | $1.76M | Buy |
42,826
+11,659
| +37% | +$483K | ﹤0.01% | 3076 |
|
|
2019
Q1 | $1.45M | Buy |
31,167
+17,560
| +129% | +$771K | ﹤0.01% | 2974 |
|
|
2018
Q4 | $593K | Sell |
13,607
-13,576
| -50% | -$678K | ﹤0.01% | 3653 |
|
|
2018
Q3 | $1.55M | Sell |
27,183
-42,420
| -61% | -$2.08M | ﹤0.01% | 3173 |
|
|
2018
Q2 | $3.38M | Buy |
69,603
+41,498
| +148% | +$1.51M | ﹤0.01% | 2067 |
|
|
2018
Q1 | $1.1M | Buy |
28,105
+22,131
| +370% | +$941K | ﹤0.01% | 3094 |
|
|
2017
Q4 | $254K | Sell |
5,974
-1,970
| -25% | -$73.9K | ﹤0.01% | 4481 |
|
|
2017
Q3 | $296K | Buy |
7,944
+7,871
| +10,782% | +$273K | ﹤0.01% | 4096 |
|
|
2017
Q2 | $3K | Sell |
73
-1,721
| -96% | -$49.9K | ﹤0.01% | 6374 |
|
|
2017
Q1 | $48K | Sell |
1,794
-13,998
| -89% | -$369K | ﹤0.01% | 5365 |
|
|
2016
Q4 | $403K | Buy |
15,792
+12,683
| +408% | +$402K | ﹤0.01% | 3574 |
|
|
2016
Q3 | $113K | Buy |
3,109
+3,068
| +7,483% | +$102K | ﹤0.01% | 4429 |
|
|
2016
Q2 | $1K | Sell |
41
-2,473
| -98% | -$80.4K | ﹤0.01% | 6202 |
|
|
2016
Q1 | $66K | Buy |
2,514
+2,024
| +413% | +$58.9K | ﹤0.01% | 4618 |
|
|
2015
Q4 | $23K | Sell |
490
-9,371
| -95% | -$337K | ﹤0.01% | 5150 |
|
|
2015
Q3 | $236K | Buy |
9,861
+9,438
| +2,231% | +$284K | ﹤0.01% | 4021 |
|
|
2015
Q2 | $13K | Sell |
423
-306
| -42% | -$9.88K | ﹤0.01% | 5962 |
|
|
2015
Q1 | $28K | Sell |
729
-786
| -52% | -$31.3K | ﹤0.01% | 5657 |
|
|
2014
Q4 | $58K | Buy |
1,515
+1,319
| +673% | +$46K | ﹤0.01% | 5606 |
|
|
2014
Q3 | $6K | Sell |
196
-145
| -43% | -$4.08K | ﹤0.01% | 7135 |
|
|
2014
Q2 | $11K | Buy |
341
+102
| +43% | +$3.41K | ﹤0.01% | 6798 |
|
|
2014
Q1 | $8K | Sell |
239
-67
| -22% | -$3.02K | ﹤0.01% | 7041 |
|
|
2013
Q4 | $12K | Buy |
+306
| New | +$7.38K | ﹤0.01% | 6947 |
|
Barclays's XLRN Position: Q4 2021 in Review
Barclays sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 111,461 shares — an estimated $19.2M sold.
Barclays first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $19.2M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Barclays reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Barclays sold 111,461 Acceleron Pharma shares in Q4 2021, an estimated $19.2M.
- Barclays first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- Barclays's Acceleron Pharma position peaked at $19.2M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.